Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Clinical trial NCT04891172 · UNKNOWN
Trial details
- NCT number
- NCT04891172
- Sponsor
- Dow University of Health Sciences
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-01
- Primary completion
- 2022-12-01
- Enrollment
- 310
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.